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Table 1 Demographic characteristics of respondents to elicitation survey and prioritisation 
survey. Of the 513 responses to elicitation survey, 31 were from respondents who completed 
the survey more than once (482 individual respondents). Data are presented as number (%) or 
median (range)
Characteristic
Elicitation survey
(n=482)
Prioritisation survey
(n=677)
Male 111 (23.0) 153 (22.6)
Female 315 (65.4) 454 (67.1)
Did not answer 56 (11.6) 70 (10.3)
Median age (range) 42 (6–82) 41 (6–82)
Category of respondent
Lay persons 224 (46.5) 314 (46.4)
  Person with 
cystic fibrosis
95 (19.7) 121 (17.9)
  Parent of person with 
cystic fibrosis 105 (21.8) 160 (23.6)
  Family and friends 24 (5.0) 33 (4,9)
Professionals 211 (43.8) 303 (44.8)
  Medical doctor 61 (12.7) 85 (12.6)
  Nurse 22 (4.6) 32 (4.7)
  Physiotherapist 49 (10.2) 65 (9.6)
  Dietitian 31 (6.4) 41 (6.1)
  Pharmacist 6 (1.2) 18 (2.7)
  Social worker 7 (1.5) 16 (2.4)
  Non-clinical researcher 10 (2.1) 7 (1.0)
  Psychologist 21 (4.4) 38 (5.6)
  Other 4 (0.8) 1 (0.1)
Did not answer 47 (9.8) 60 (8.9)
Country
  UK 249 (51.7) 474 (70.0)
  USA and Canada 91 (18.9) 70 (10.3)
  Rest of Europe 45 (9.3) 42 (6.2)
  Australia and New 
Zealand
35 (7.3) 22 (3.2)
  Other 5 (1.0) 5 (0.7)
Did not answer 57 (11.8) 64 (9.5)
The top 10 research 
priorities in cystic fibrosis 
developed by a partnership 
between people with CF and 
healthcare providers
AbsTrACT 
There remain many treatment uncertainties 
in cystic fibrosis (CF). With limited resources, 
research should focus on questions which 
are most important to the CF community. 
We conducted a James Lind Alliance Priority 
Setting Partnership in CF. Research questions 
were elicited and then prioritised in successive 
surveys. A workshop agreed the final top 
10. Online methods avoided cross infection 
and widened participation. The elicitation 
survey had 482 respondents (1080 questions) 
and prioritisation survey 677 respondents. 
Participants were drawn equally from the 
patient and clinical communities globally. We 
have achieved a consensus on 10 research 
priorities which will be attractive to funders.
InTroduCTIon
Therapies targeting the basic defect of cystic 
fibrosis (CF) are now available in the clin-
ic, with more in development.1 However, 
conventional therapies for persistent airway 
infection and pancreatic malabsorption are 
still required and there remain many treat-
ment uncertainties, which have yet to be 
clarified through well designed and ade-
quately powered clinical trials.2
Both the Patient-Centered Outcomes 
Research Institute, in the USA, and the 
National Institute for Health Research 
(NIHR), in the UK, support patient in-
volvement and ‘co-production’ of re-
search.3 However, there has been no sys-
tematic and inclusive dialogue between 
clinicians, patients and parents about pri-
orities for clinical research in CF. Face-to-
face contact between patients is precluded 
due to risk of transmission of organisms 
such as Pseudomonas aeruginosa, provid-
ing a challenge to consultative exercises 
involving patients with CF.4
The NIHR James Lind Alliance (JLA) 
supports Priority Setting Partnerships 
which bring patients, carers and clinicians 
together to prioritise research questions. 
Outcomes from JLA Priority Setting Part-
nerships have a track record of attracting 
significant research funding.5 We conduct-
ed a JLA Priority Setting Partnership in CF 
to identify the key treatment uncertainties 
for the CF community and produce the 
top 10 research questions for treatment 
and management of CF.
METhods
Our Priority Setting Partnership took 
place in March 2016–January 2017. 
We published our protocol before com-
mencing (http:// eprints. nottingham. ac. 
uk/ 35223/). We followed JLA methodol-
ogy,6 adapting the process using online 
methods to avoid risk of cross infection. 
Our steering group was selected to in-
clude lay members (two people with CF 
and two parents) and professionals from 
each discipline: two respiratory paedia-
tricians, respiratory physician, physio-
therapist, dietitian, nurse, pharmacist, 
clinical psychologist and social worker. 
We also included a specialist commis-
sioner, UK Cystic Fibrosis Trust repre-
sentative and four academics (systematic 
reviewer, qualitative researcher, project 
manager and academic clinical fellow).
From March to June 2016, we conduct-
ed the first of two online surveys (Survey 
Monkey). The elicitation survey requested 
respondent demographics and asked a single 
question ‘What question on Cystic Fibrosis 
would you like to see answered by research?’ 
Respondents could submit up to five ques-
tions. The survey was advertised through 
professional groups, clinic posters and our 
bespoke Twitter account (@questionCF).
Two researchers (NR and SS) inde-
pendently reviewed all questions submitted 
with adjudication by the steering group. 
Non-questions and questions unrelated to 
treatment were removed. We conducted a 
systematic review of evidence gaps in CF7 
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Figure 1 (A) James Lind Alliance Priority Setting Partnership in CF. Flow chart of submitted 
questions, showing the process for selecting the final top 20. (B) The top 10 questions for clinical 
research in cystic fibrosis.
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and excluded any questions already an-
swered. Where several questions addressed 
the same issue, they were consolidated into 
a single ‘standardised question’.
The steering group undertook a Delphi8 
assessment of the standardised questions to 
produce a shortlist for the prioritisation sur-
vey. This allowed participants to rank their 
top 10 questions (September–November 
2016). The prioritisation survey was adver-
tised through Twitter and by emailing partic-
ipants who completed the elicitation survey.
The top 20 questions chosen through the 
prioritisation survey were then discussed at 
a workshop in January 2017. Lay and pro-
fessional participants (recruited through the 
prioritisation survey), all with equal voice, 
led by three independent JLA facilitators, 
selected the final top 10 research priorities, 
through a process of small group discussion 
and plenary voting. Patient representatives 
joined remotely from home and hospital us-
ing video conferencing.
rEsulTs
We had 513 replies to the elicitation survey, 
of which 31 completed the survey more 
than once, leaving 482 respondents who 
submitted 1080 questions. Table 1 shows 
the demographics of elicitation survey re-
spondents. There were 224 (46.5%) lay re-
spondents, 211 (43.8%) professionals and 
47 (9.8%) were unknown. Just over half 
were from the UK, with submissions from 
23 countries in total.
Figure 1A describes how the questions 
were sorted and refined. There were 704 
treatment and management questions which 
were combined into 127 standardised ques-
tions. Following the Delphi process, 71 
questions were taken forward for prioriti-
sation. The prioritisation survey was com-
pleted by 677 respondents (see table 1 for 
demographics). The final top 10 questions 
are shown in figure  1B.
dIsCussIon
We have undertaken the first JLA Priority 
Setting Partnership in CF, with equal num-
bers of participants from the patient and 
clinical communities. We have produced a 
top 10 list of clinical research questions in 
CF, which will be attractive to both research-
ers and funders.
There has been little previous work of 
this kind. The Italian Patient-Centered 
Outcomes CF Research Group canvassed 
opinion from 12 clinical researchers and 
eight ‘expert stakeholders’.9 This exercise 
prioritised five topics: transplantation, Cyst-
ic Fibrosis Transmembrane Conductance 
Regulator (CFTR) modulators, P. aerug-
inosa, Burkholderia cepacia and allergic 
bronchopulmonary aspergillosis. The man-
agement of infection in CF also featured in 
our top 10—non-tuberculous mycobacteria 
(Q3) and P. aeruginosa (Q10). Infection with 
P. aeruginosa has previously been shown to 
be a great concern to parents and patients 
with CF.10 Surprisingly, questions on CFTR 
modulators were absent from our top 10. 
Respondents might assume this research will 
progress whether or not prioritised.
The strength of our study is our global 
reach and the large numbers of respond-
ents, representing the whole CF community. 
Online surveys give less granular data than 
approaches such as focus groups. An alterna-
tive approach to ours—focus groups, using 
video conferencing—would also avoid cross 
infection. Key aspects of our robust meth-
odology were a representative steering com-
mittee, a systematic review of research gaps 
and having two researchers independently 
processing questions. Our experience of us-
ing online surveys, promotion through social 
media and video conferencing may be useful 
to other patient engagement exercises in res-
piratory medicine and beyond where face-
to-face meetings are restricted by infection 
control, geography or frailty of participants. 
The US CF Foundation ‘Insight CF’ engage-
ment programme has adopted a similar ap-
proach to registry-based research.
The items on the top 10 list are not 
prescriptive, rather they allow research 
groups to formulate a testable hypothesis 
with the appropriate study design. We are 
in discussion with the NIHR Evaluation, 
Trials and Studies Coordinating Centre 
about topics from our top 10, suitable for 
NIHR-commissioned research. We hope 
that this exercise will invigorate research 
in areas of shared importance to both the 
patient and the clinical community and 
demonstrate the value of involving the 
whole CF community in all steps of the 
research pathway.
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